Stay updated on Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page
- Check5 days agoChange DetectedRevision metadata updated from v3.4.2 to v3.4.3. No user-facing content or functionality changes.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Plain Language Summary and data-sharing links (Trialstransparency PDF, externaldatasharing-msd). Removed older EngageZone data-sharing documents and updated revision to v3.4.2.SummaryDifference0.2%

- Check41 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0; this appears to be revision metadata only. No study content such as eligibility criteria, locations, or outcomes has changed.SummaryDifference0.0%

- Check48 days agoChange DetectedAdded: Show glossary, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0. Removed: Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.1%

- Check62 days agoChange DetectedThe page shows a minor revision update from v3.3.3 to v3.3.4; no content changes to the study details or documents are apparent. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check83 days agoChange DetectedLocations have been added and updated across numerous regions worldwide, expanding the list of study sites. This expands enrollment access by giving participants more nearby sites and clearer site information.SummaryDifference4%

Stay in the know with updates to Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.